BRAF Inhibitors for BRAF V600E Mutant Colorectal Cancers: Literature Survey and Case Report
The main method of fighting against colon cancer is targeted treatment. BRAF inhibitors, which are accepted as standard treatment for V600E mutant malign melanomas, are the newest approach for targeted treatment of V600E mutant colorectal cancers. In this case report, we share our experience about t...
Saved in:
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2018-01-01
|
| Series: | Case Reports in Surgery |
| Online Access: | http://dx.doi.org/10.1155/2018/8782328 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832568411577647104 |
|---|---|
| author | Yasar Subutay Peker Mehmet Fatih Can Ismail Hakki Ozerhan Gokhan Yagci Nazif Zeybek Kutan Kavakli Sedat Gurkok Alper Gozubuyuk Onur Genc Gokhan Erdem Ahmet Ozet Mustafa Gerek Yusuf Peker |
| author_facet | Yasar Subutay Peker Mehmet Fatih Can Ismail Hakki Ozerhan Gokhan Yagci Nazif Zeybek Kutan Kavakli Sedat Gurkok Alper Gozubuyuk Onur Genc Gokhan Erdem Ahmet Ozet Mustafa Gerek Yusuf Peker |
| author_sort | Yasar Subutay Peker |
| collection | DOAJ |
| description | The main method of fighting against colon cancer is targeted treatment. BRAF inhibitors, which are accepted as standard treatment for V600E mutant malign melanomas, are the newest approach for targeted treatment of V600E mutant colorectal cancers. In this case report, we share our experience about the use of BRAF inhibitor vemurafenib on a V600E mutant metastatic right colon adenocarcinoma patient. A 59-year-old male with only lung multiple metastatic V600E mutant right colon cancer presented to our clinic. The patient was evaluated and FOLFOX + bevacizumab treatment was initiated, which was then continued with vemurafenib. A remarkable response was achieved with vemurafenib treatment in which the drug resistance occurred approximately in the sixth month. Even though the patient benefited majorly from vemurafenib, he died on the 20th month of the diagnosis. The expected overall survival for metastatic V600E mutant colon adenocarcinoma patients is 4.7 months. BRAF inhibitors provide new treatment alternatives for V600E mutant colorectal cancers, with prolonged overall survival. BRAF inhibitors in combination with MEK inhibitors are reported as feasible treatment to overcome BRAF inhibitor drug resistance on which phase studies are still in progress. To conclude, BRAF inhibitors alone or in combination with other drugs provide a chance for curing BRAF V600E mutant colorectal cancer patients. |
| format | Article |
| id | doaj-art-17753d1cf366468c9b94b7a4d65b2878 |
| institution | Kabale University |
| issn | 2090-6900 2090-6919 |
| language | English |
| publishDate | 2018-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Case Reports in Surgery |
| spelling | doaj-art-17753d1cf366468c9b94b7a4d65b28782025-02-03T00:59:07ZengWileyCase Reports in Surgery2090-69002090-69192018-01-01201810.1155/2018/87823288782328BRAF Inhibitors for BRAF V600E Mutant Colorectal Cancers: Literature Survey and Case ReportYasar Subutay Peker0Mehmet Fatih Can1Ismail Hakki Ozerhan2Gokhan Yagci3Nazif Zeybek4Kutan Kavakli5Sedat Gurkok6Alper Gozubuyuk7Onur Genc8Gokhan Erdem9Ahmet Ozet10Mustafa Gerek11Yusuf Peker12Department of General Surgery, Gulhane Training and Research Hospital, University of Medical Sciences, Ankara, TurkeyDepartment of General Surgery, Gulhane Training and Research Hospital, University of Medical Sciences, Ankara, TurkeyDepartment of General Surgery, Gulhane Training and Research Hospital, University of Medical Sciences, Ankara, TurkeyDepartment of General Surgery, Guven Hospital, Ankara, TurkeyDepartment of General Surgery, Gulhane Training and Research Hospital, University of Medical Sciences, Ankara, TurkeyDepartment of Thoracic Surgery, Gulhane Training and Research Hospital, University of Medical Sciences, Ankara, TurkeyDepartment of Thoracic Surgery, Gulhane Training and Research Hospital, University of Medical Sciences, Ankara, TurkeyDepartment of Thoracic Surgery, Gulhane Training and Research Hospital, University of Medical Sciences, Ankara, TurkeyDepartment of Thoracic Surgery, Gulhane Training and Research Hospital, University of Medical Sciences, Ankara, TurkeyDepartment of Medical Oncology, Liv Hospital, Istanbul, TurkeyDepartment of Medical Oncology, Gazi University Hospital, Ankara, TurkeyDepartment of Otorhinolaryngology, University of Medical Sciences, Ankara, TurkeyDepartment of General Surgery, Gulhane Military Medical Academy, Ankara, TurkeyThe main method of fighting against colon cancer is targeted treatment. BRAF inhibitors, which are accepted as standard treatment for V600E mutant malign melanomas, are the newest approach for targeted treatment of V600E mutant colorectal cancers. In this case report, we share our experience about the use of BRAF inhibitor vemurafenib on a V600E mutant metastatic right colon adenocarcinoma patient. A 59-year-old male with only lung multiple metastatic V600E mutant right colon cancer presented to our clinic. The patient was evaluated and FOLFOX + bevacizumab treatment was initiated, which was then continued with vemurafenib. A remarkable response was achieved with vemurafenib treatment in which the drug resistance occurred approximately in the sixth month. Even though the patient benefited majorly from vemurafenib, he died on the 20th month of the diagnosis. The expected overall survival for metastatic V600E mutant colon adenocarcinoma patients is 4.7 months. BRAF inhibitors provide new treatment alternatives for V600E mutant colorectal cancers, with prolonged overall survival. BRAF inhibitors in combination with MEK inhibitors are reported as feasible treatment to overcome BRAF inhibitor drug resistance on which phase studies are still in progress. To conclude, BRAF inhibitors alone or in combination with other drugs provide a chance for curing BRAF V600E mutant colorectal cancer patients.http://dx.doi.org/10.1155/2018/8782328 |
| spellingShingle | Yasar Subutay Peker Mehmet Fatih Can Ismail Hakki Ozerhan Gokhan Yagci Nazif Zeybek Kutan Kavakli Sedat Gurkok Alper Gozubuyuk Onur Genc Gokhan Erdem Ahmet Ozet Mustafa Gerek Yusuf Peker BRAF Inhibitors for BRAF V600E Mutant Colorectal Cancers: Literature Survey and Case Report Case Reports in Surgery |
| title | BRAF Inhibitors for BRAF V600E Mutant Colorectal Cancers: Literature Survey and Case Report |
| title_full | BRAF Inhibitors for BRAF V600E Mutant Colorectal Cancers: Literature Survey and Case Report |
| title_fullStr | BRAF Inhibitors for BRAF V600E Mutant Colorectal Cancers: Literature Survey and Case Report |
| title_full_unstemmed | BRAF Inhibitors for BRAF V600E Mutant Colorectal Cancers: Literature Survey and Case Report |
| title_short | BRAF Inhibitors for BRAF V600E Mutant Colorectal Cancers: Literature Survey and Case Report |
| title_sort | braf inhibitors for braf v600e mutant colorectal cancers literature survey and case report |
| url | http://dx.doi.org/10.1155/2018/8782328 |
| work_keys_str_mv | AT yasarsubutaypeker brafinhibitorsforbrafv600emutantcolorectalcancersliteraturesurveyandcasereport AT mehmetfatihcan brafinhibitorsforbrafv600emutantcolorectalcancersliteraturesurveyandcasereport AT ismailhakkiozerhan brafinhibitorsforbrafv600emutantcolorectalcancersliteraturesurveyandcasereport AT gokhanyagci brafinhibitorsforbrafv600emutantcolorectalcancersliteraturesurveyandcasereport AT nazifzeybek brafinhibitorsforbrafv600emutantcolorectalcancersliteraturesurveyandcasereport AT kutankavakli brafinhibitorsforbrafv600emutantcolorectalcancersliteraturesurveyandcasereport AT sedatgurkok brafinhibitorsforbrafv600emutantcolorectalcancersliteraturesurveyandcasereport AT alpergozubuyuk brafinhibitorsforbrafv600emutantcolorectalcancersliteraturesurveyandcasereport AT onurgenc brafinhibitorsforbrafv600emutantcolorectalcancersliteraturesurveyandcasereport AT gokhanerdem brafinhibitorsforbrafv600emutantcolorectalcancersliteraturesurveyandcasereport AT ahmetozet brafinhibitorsforbrafv600emutantcolorectalcancersliteraturesurveyandcasereport AT mustafagerek brafinhibitorsforbrafv600emutantcolorectalcancersliteraturesurveyandcasereport AT yusufpeker brafinhibitorsforbrafv600emutantcolorectalcancersliteraturesurveyandcasereport |